JHS acquired the tech transfer for a COVID-19 liquid suspension vaccine product that was approved for use internationally, but not within the United States. This transfer was completed in the less than half the time typically required. The challenge was developing a process to produce the vaccine in the US that did not compromise the sterility, or homogeneity, of the product

Read the full case study by completing the form below.